In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxigene Neu-Sensamide NDA may reference Sensamide pivotal data, FDA has told company -- CEO.

Executive Summary

OXIGENE NEU-SENSAMIDE RADIATION SENSITIZER ON TRACK FOR 1998 NDA filing, Oxigene CEO Bjorn Nordenvall, PhD, indicated during a UBS Securities conference in London April 15. A Phase III trial of the high-dose metoclopramide formulation will be completed by the second quarter of 1998, putting the drug on track for a 1999 launch, Nordenvall estimated. The company plans to use a Phase III trial of an earlier formulation, Sensamide, to support the application. FDA has told the company that data from the two formulations can be included in the Neu-Sensamide NDA, Nordenvall said.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel